13F Holdings
中文EN

SIGY Sigyn Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1642159 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.3%
TTM EPS YoY39.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,144.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets4,464.7%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-811.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue—————
R&D expense$773,279$798,165$657,657$734,014$419,362
SG&A expense$1.74M$1.66M$1.49M$1.27M$496,367
Operating income-$2.52M-$2.46M-$2.15M-$2.01M-$916,434
Interest expense———$30,800$343,156
Pretax income-$3.34M-$4.15M-$2.93M-$3.00M-$1.26M
Net income-$3.34M-$4.15M-$2.93M-$3.00M-$1.26M
EBITDA-$2.51M-$2.45M-$2.14M-$2.01M-$916,088
EPS (basic)-2.51-3.77-3.13-0.08-0.17
EPS (diluted)-2.51-3.77-3.13-0.08-0.17
Weighted avg. shares (diluted)1.33M1.10M934,91536.40M7.35M
Balance sheet
Cash & equivalents$12,144$11,690$8,356$340,956$84,402
Inventory—$50,000$50,000$50,000$586,047
Current assets$21,244$118,063$70,298$393,031$670,449
PP&E, net$9,685$15,296$22,052$28,046$1,728
Intangibles——$2,100$5,700$21,905
Total assets$213,719$321,806$332,879$710,259$694,082
Current liabilities$4.61M$3.61M$2.05M$734,218$594,903
Short-term debt$0————
Long-term debt$2.02M$2.51M$2.28M——
Total debt$2.02M$2.51M$2.28M——
Total liabilities$4.67M$3.73M$2.24M$974,843$594,903
Shareholders' equity-$4.46M-$3.41M-$1.90M-$264,584$99,179
Net debt$2.01M$2.50M$2.27M——
Shares outstanding1.61M1.29M956,59537.30M35.20M
Cash flow statement
Operating cash flow-$872,436-$1.38M-$1.83M-$1.77M-$829,809
Capital expenditure——$860$29,264—
Free cash flow——-$1.83M-$1.80M—
Investing cash flow——-$860-$29,264-$10,799
Financing cash flow$872,890$1.39M$1.50M$2.06M$925,010
Depreciation & amortization$5,611$6,756$6,854$2,946$346
Stock-based compensation$150,000$215,558——$0

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.